Latest Serotonin-norepinephrine reuptake inhibitor Stories
Only 41 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources Patient-Flow Models Need to Take Into Account Effexor XR's More Frequent Use in Early Lines of Therapy Compared With Cymbalta WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that one third of surveyed psychiatrists and two...
STAMFORD, Conn., May 7 /PRNewswire/ -- RYZOLT(TM) (tramadol HCl extended-release tablets) is now available from Purdue Pharma L.P. for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.
NEW YORK and SAN DIEGO, April 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc.
NEW YORK and SAN DIEGO, March 6, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc.
New treatment option for the estimated 6 million Americans living with this chronic, debilitating condition NEW YORK and SAN DIEGO, Jan. 14, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc.
The use of antidepressant medications by patients with fibromyalgia syndrome is associated with a reduction in pain, sleep disturbances and depressed mood and improvement of health-related quality of life.
Eli Lilly and Company has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on a Cymbalta application for the treatment of fibromyalgia.
INDIANAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta(R) (duloxetine hydrochloride) application for the treatment of fibromyalgia.
COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults.
Adheris, Inc., a leader in patient adherence and education programs, announced today the results of a new study that examined adherence rates among patients on SSRI/SNRI antidepressant therapy.
- A volcanic mudflow.